CY1121159T1 - Μη-ενσωματουμενοι λεντiϊικοι φορεις - Google Patents
Μη-ενσωματουμενοι λεντiϊικοι φορειςInfo
- Publication number
- CY1121159T1 CY1121159T1 CY20181101398T CY181101398T CY1121159T1 CY 1121159 T1 CY1121159 T1 CY 1121159T1 CY 20181101398 T CY20181101398 T CY 20181101398T CY 181101398 T CY181101398 T CY 181101398T CY 1121159 T1 CY1121159 T1 CY 1121159T1
- Authority
- CY
- Cyprus
- Prior art keywords
- glycoprotein
- variant
- linter
- bodies
- integrated
- Prior art date
Links
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- 101500008206 Sindbis virus Spike glycoprotein E2 Proteins 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 229920002971 Heparan sulfate Polymers 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36145—Special targeting system for viral vectors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Παρέχονται σωματίδια λεντιϊικού φορέα τα οποία περιλαμβάνουν μια παραλλαγή Ε2 γλυκοπρωτεΐνης ιού Sindbis και ένα γονιδίωμα λεντιϊικού φορέα το οποίο περιλαμβάνει μια αλληλουχία ενδιαφέροντος. Ένα σωματίδιο λεντιϊικού φορέα το οποίο περιλαμβάνει: (α) έναν φάκελο ο οποίος περιλαμβάνει μια παραλλαγή Ε2 γλυκοπρωτεΐνης ιού Sindbis• και (β) ένα γονιδίωμα λεντιϊικού φορέα το οποίο περιλαμβάνει μια αλληλουχία ενδιαφέροντος• όπου η παραλλαγή Ε2 γλυκοπρωτεΐνης διευκολύνει τη μόλυνση δενδριτικών κυττάρων από το σωματίδιο λεντιϊικού φορέα, και όπου η παραλλαγή Ε2 γλυκοπρωτεΐνης έχει μειωμένη πρόσδεση σε θειική ηπαράνη σε σύγκριση με μια αλληλουχία αναφοράς (HR στέλεχος).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22849109P | 2009-07-24 | 2009-07-24 | |
PCT/US2010/042870 WO2011011584A1 (en) | 2009-07-24 | 2010-07-22 | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
EP10737715.2A EP2456786B2 (en) | 2009-07-24 | 2010-07-22 | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121159T1 true CY1121159T1 (el) | 2020-05-29 |
Family
ID=42727669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181101398T CY1121159T1 (el) | 2009-07-24 | 2018-12-27 | Μη-ενσωματουμενοι λεντiϊικοι φορεις |
Country Status (28)
Country | Link |
---|---|
US (3) | US20110064763A1 (el) |
EP (2) | EP2456786B2 (el) |
JP (4) | JP2013500015A (el) |
KR (1) | KR101790187B1 (el) |
CN (1) | CN102482329B (el) |
AU (1) | AU2010276194B2 (el) |
BR (1) | BR112012001653A2 (el) |
CA (1) | CA2768938C (el) |
CY (1) | CY1121159T1 (el) |
DK (2) | DK2456786T4 (el) |
EA (1) | EA032403B1 (el) |
ES (2) | ES2702274T3 (el) |
HK (1) | HK1201557A1 (el) |
HR (2) | HRP20140327T4 (el) |
HU (1) | HUE043032T2 (el) |
IL (1) | IL217679A (el) |
LT (1) | LT2770061T (el) |
ME (1) | ME01720B (el) |
MX (1) | MX2012001075A (el) |
NZ (1) | NZ597804A (el) |
PL (2) | PL2456786T5 (el) |
PT (2) | PT2456786E (el) |
RS (2) | RS58042B1 (el) |
SG (1) | SG177744A1 (el) |
SI (2) | SI2770061T1 (el) |
SM (1) | SMT201400041B (el) |
TR (1) | TR201819229T4 (el) |
WO (1) | WO2011011584A1 (el) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2015133046A (ru) * | 2009-07-15 | 2018-12-24 | Кэлиммьюн Инк. | Двойной вектор для подавления вируса иммунодефицита человека |
AU2012217723A1 (en) * | 2011-02-15 | 2013-08-29 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
CA2863658C (en) * | 2012-02-03 | 2023-03-14 | Emory University | Immunostimulatory compositions, particles, and uses related thereto |
EP2844746A4 (en) | 2012-03-26 | 2016-07-20 | Univ California | LENTIVIRUS PSEUDOTYPED WITH NIPAH VIRUS ENVELOPE AND METHODS OF USE |
US9713635B2 (en) * | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
US8323662B1 (en) * | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
EP2831095B1 (en) * | 2012-03-30 | 2018-11-28 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign |
EA034351B1 (ru) | 2012-05-16 | 2020-01-30 | Иммьюн Дизайн Корп. | Трехкомпонентная вакцина против впг-2 и способы ее применения |
WO2014109728A1 (en) * | 2013-01-11 | 2014-07-17 | The Scripps Research Institute | Methods and compositions for enchancing transduction efficiency of retroviral vectors |
GB201308772D0 (en) * | 2013-05-15 | 2013-06-26 | Imp Innovations Ltd | Vectors |
HUE051311T2 (hu) | 2014-03-09 | 2021-03-01 | Univ Pennsylvania | Ornitin transzkarbamiláz (TC) deficiencia kezelésében alkalmas készítmények |
JP2017522312A (ja) | 2014-07-15 | 2017-08-10 | イミューン デザイン コーポレイション | Tlr4アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン |
EP3247409B1 (en) * | 2015-01-21 | 2020-11-04 | Cornell University | Viral vectors for prophylaxis and therapy of hemoglobinopathies |
CN112481211B (zh) * | 2015-01-26 | 2024-07-05 | 儿童医院公司 | 免疫调节性提高的细胞及其使用和生产方法 |
RU2017132190A (ru) * | 2015-03-18 | 2019-04-18 | Омнисайт | Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними |
CN108026593A (zh) | 2015-05-18 | 2018-05-11 | 卡琳缪恩股份有限公司 | 区分hiv-1与慢病毒载体的方法 |
KR20180043800A (ko) | 2015-09-09 | 2018-04-30 | 이뮨 디자인 코포레이션 | Ny-eso-1 특이적 tcrs 및 그의 사용 방법 |
MX2018005467A (es) * | 2015-11-09 | 2018-12-11 | Immune Design Corp | Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas. |
US11135283B2 (en) | 2015-11-09 | 2021-10-05 | Immune Design Corp. | Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids |
AU2017223460A1 (en) | 2016-02-23 | 2018-09-13 | Immune Design Corp. | Multigenome retroviral vector preparations and methods and systems for producing and using same |
CA3015530A1 (en) * | 2016-03-04 | 2017-09-08 | New York University | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity |
EP3443000A2 (en) | 2016-04-15 | 2019-02-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
EP3442999A2 (en) | 2016-04-15 | 2019-02-20 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
EP3235828A1 (en) * | 2016-04-21 | 2017-10-25 | Genethon | Stable pseudotyped lentiviral particles and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
KR20190099194A (ko) | 2016-10-20 | 2019-08-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 분비가능한 변이체 면역조절 단백질 및 조작된 세포 치료 |
WO2018148180A2 (en) | 2017-02-07 | 2018-08-16 | Immune Design Corp. | Materials and methods for identifying and treating cancer patients |
WO2018170023A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
EP3596116B1 (en) | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
KR20200034668A (ko) | 2017-05-08 | 2020-03-31 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 막 융합을 촉진시키기 위한 조성물 및 그의 용도 |
CA3078517A1 (en) | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
US11116833B2 (en) * | 2018-02-08 | 2021-09-14 | George Mason University | Method and system for inactivating virus infectivity for producing live-attenuated vaccines |
US20210363219A1 (en) | 2018-06-15 | 2021-11-25 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
JP2022510276A (ja) | 2018-11-30 | 2022-01-26 | アルパイン イミューン サイエンシズ インコーポレイテッド | Cd86バリアント免疫調節タンパク質およびその使用 |
JP7495435B2 (ja) | 2019-06-14 | 2024-06-04 | ザ ジェイ. デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デビッド グラッドストーン | 治療用干渉粒子による免疫不全ウイルス感染を処置するための組成物及び方法 |
US20220307050A1 (en) * | 2019-08-01 | 2022-09-29 | The Regents Of The University Of California | Non-viral transgenesis |
CN110982842B (zh) * | 2019-12-31 | 2023-04-18 | 山西大学 | 一种慢病毒表达载体的设计及应用 |
EP4320242A1 (en) | 2021-04-08 | 2024-02-14 | Sana Biotechnology, Inc. | Cd8-specific antibody constructs and compositions thereof |
US20230340627A1 (en) * | 2022-04-05 | 2023-10-26 | Bio-Rad Laboratories, Inc. | Analysis of viral particles by digital assay |
WO2023220603A1 (en) | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US4569794A (en) | 1984-12-05 | 1986-02-11 | Eli Lilly And Company | Process for purifying proteins and compounds useful in such process |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
DE68918494T2 (de) | 1988-05-17 | 1995-03-23 | Lubrizol Genetics Inc | Pflanzliches Ubiquitinpromotorsystem. |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5298420A (en) | 1990-08-03 | 1994-03-29 | Tanox Biosystems, Inc. | Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface |
TW279133B (el) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
JPH08504091A (ja) | 1992-09-22 | 1996-05-07 | メディカル・リサーチ・カウンシル | 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス |
US6534051B1 (en) | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
US5279552A (en) | 1993-01-11 | 1994-01-18 | Anton Magnet | Intradermal injection device |
US5997501A (en) | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US5660835A (en) | 1995-02-24 | 1997-08-26 | East Carolina University | Method of treating adenosine depletion |
AU727531B2 (en) | 1995-07-25 | 2000-12-14 | Crucell Holland B.V. | Methods and means for targeted gene delivery |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
FR2747046B1 (fr) | 1996-04-05 | 1998-06-19 | Univ Paris Curie | Nouveaux vaccins issus de plasmovirus |
WO1998032869A1 (en) | 1997-01-29 | 1998-07-30 | Neurosearch A/S | Expression vectors and methods for in vivo expression of therapeutic polypeptides |
US6432699B1 (en) * | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
US6531123B1 (en) | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
WO1999013905A1 (en) | 1997-09-18 | 1999-03-25 | The Trustees Of The University Of Pennsylvania | Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery |
ZA988446B (en) | 1997-09-18 | 2000-03-22 | Res Dev Foundation | Production of vaccines using arthropod vectored viruses. |
US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
AU763007B2 (en) * | 1998-05-22 | 2003-07-10 | Oxford Biomedica (Uk) Limited | Retroviral delivery system |
WO2000055335A1 (en) * | 1999-03-16 | 2000-09-21 | Dana-Farber Cancer Institute, Inc. | Pseudotyped lentiviral vectors and uses thereof |
CA2373300C (en) | 1999-04-14 | 2012-02-21 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
EP1046651A1 (en) | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
EP1214437A1 (en) | 1999-08-27 | 2002-06-19 | The Regents of the University of California | Use of lentiviral vectors for antigen presentation in dendritic cells |
ES2337017T3 (es) | 1999-10-13 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Procedimiento para obtener respuestas inmunitarias celulares de proteinas. |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
US6569143B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Method of intradermally injecting substances |
US6776776B2 (en) | 1999-10-14 | 2004-08-17 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
US20020193740A1 (en) | 1999-10-14 | 2002-12-19 | Alchas Paul G. | Method of intradermally injecting substances |
US7241275B2 (en) | 1999-10-14 | 2007-07-10 | Becton, Dickinson And Company | Intradermal needle |
US6627442B1 (en) * | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
CA2439620A1 (en) * | 2001-03-02 | 2002-09-12 | Merck & Co., Inc. | Viral reporter particles |
CA2449589A1 (en) * | 2001-06-08 | 2002-12-19 | Dnavec Research Inc. | Gene transfer into primate embryonic stem cells using vsv-g pseudotyped simian immunodeficiency virus vector |
EP1425400B1 (en) | 2001-09-13 | 2016-11-02 | California Institute Of Technology | Method for producing transgenic animals |
US7732193B2 (en) | 2001-09-13 | 2010-06-08 | California Institute Of Technology | Method for expression of small RNA molecules within a cell |
US7195916B2 (en) | 2001-09-13 | 2007-03-27 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
US7737124B2 (en) | 2001-09-13 | 2010-06-15 | California Institute Of Technology | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
WO2003041763A2 (en) | 2001-11-14 | 2003-05-22 | Medical Instill Technologies, Inc. | Intradermal delivery device and method |
CA2474742C (en) | 2002-02-04 | 2012-01-17 | Becton, Dickinson And Company | Dermal access member |
US7115108B2 (en) | 2002-04-02 | 2006-10-03 | Becton, Dickinson And Company | Method and device for intradermally delivering a substance |
US6780171B2 (en) | 2002-04-02 | 2004-08-24 | Becton, Dickinson And Company | Intradermal delivery device |
US7047070B2 (en) | 2002-04-02 | 2006-05-16 | Becton, Dickinson And Company | Valved intradermal delivery device and method of intradermally delivering a substance to a patient |
ATE424464T1 (de) * | 2002-04-26 | 2009-03-15 | Inst Nat Sante Rech Med | Verbesserte chimäre glykoproteine und pseudotypisierte lentivirale vektoren |
US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
EP1535627B1 (en) | 2002-08-16 | 2008-07-09 | Japan Science and Technology Agency | Recombinant bcg vaccine |
AU2003297474A1 (en) | 2002-12-18 | 2004-07-14 | Salk Institute For Biological Studies | Methods of inhibiting gene expression by rna interference |
US7090837B2 (en) | 2003-01-21 | 2006-08-15 | The Salk Institute For Biological Studies | Compositions and methods for tissue specific targeting of lentivirus vectors |
US7786288B2 (en) | 2003-10-23 | 2010-08-31 | Karp Nelson M | Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site |
US7108679B2 (en) | 2004-03-11 | 2006-09-19 | Becton, Dickinson And Company | Intradermal syringe and needle assembly |
US20070275873A1 (en) * | 2004-04-29 | 2007-11-29 | Heidner Hans W | Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting |
WO2005118802A2 (en) | 2004-06-03 | 2005-12-15 | The Regents Of The University Of California | Targeting pseudotyped retroviral vectors |
GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
WO2006031996A2 (en) * | 2004-09-14 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeting viruses using a modified sindbis glycoprotein |
RU2007134371A (ru) * | 2005-02-16 | 2009-03-27 | Лентиджен Корпорейшн (Us) | Лентивирусные векторы и их применение |
WO2006130855A2 (en) | 2005-06-01 | 2006-12-07 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
PL2048955T3 (pl) | 2006-07-21 | 2013-11-29 | California Inst Of Techn | Nakierowane dostarczanie genu dla szczepienia komórek dendrytycznych |
PT2486938T (pt) | 2006-09-26 | 2018-06-12 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
CA2698668A1 (en) | 2007-09-07 | 2009-03-19 | University Of Georgia Research Foundation, Inc. | Synthetic lipid a derivative |
DK2222861T3 (en) | 2007-12-11 | 2018-02-05 | Univ North Carolina Chapel Hill | POLYPURIN-TRACT MODIFIED RETROVIRAL VECTORS |
-
2010
- 2010-07-22 NZ NZ597804A patent/NZ597804A/xx not_active IP Right Cessation
- 2010-07-22 PT PT107377152T patent/PT2456786E/pt unknown
- 2010-07-22 PT PT13194273T patent/PT2770061T/pt unknown
- 2010-07-22 JP JP2012521778A patent/JP2013500015A/ja not_active Withdrawn
- 2010-07-22 SI SI201031821T patent/SI2770061T1/sl unknown
- 2010-07-22 AU AU2010276194A patent/AU2010276194B2/en not_active Ceased
- 2010-07-22 EA EA201270191A patent/EA032403B1/ru not_active IP Right Cessation
- 2010-07-22 DK DK10737715.2T patent/DK2456786T4/en active
- 2010-07-22 WO PCT/US2010/042870 patent/WO2011011584A1/en active Application Filing
- 2010-07-22 TR TR2018/19229T patent/TR201819229T4/tr unknown
- 2010-07-22 PL PL10737715T patent/PL2456786T5/pl unknown
- 2010-07-22 BR BR112012001653A patent/BR112012001653A2/pt not_active Application Discontinuation
- 2010-07-22 MX MX2012001075A patent/MX2012001075A/es active IP Right Grant
- 2010-07-22 CN CN201080040409.6A patent/CN102482329B/zh active Active
- 2010-07-22 KR KR1020127004625A patent/KR101790187B1/ko active IP Right Grant
- 2010-07-22 HU HUE13194273A patent/HUE043032T2/hu unknown
- 2010-07-22 CA CA2768938A patent/CA2768938C/en active Active
- 2010-07-22 ME MEP-2014-29A patent/ME01720B/me unknown
- 2010-07-22 SG SG2012005146A patent/SG177744A1/en unknown
- 2010-07-22 PL PL13194273T patent/PL2770061T3/pl unknown
- 2010-07-22 LT LTEP13194273.2T patent/LT2770061T/lt unknown
- 2010-07-22 ES ES13194273T patent/ES2702274T3/es active Active
- 2010-07-22 SI SI201030576T patent/SI2456786T2/sl unknown
- 2010-07-22 RS RS20181505A patent/RS58042B1/sr unknown
- 2010-07-22 ES ES10737715.2T patent/ES2455544T5/es active Active
- 2010-07-22 DK DK13194273.2T patent/DK2770061T3/en active
- 2010-07-22 EP EP10737715.2A patent/EP2456786B2/en active Active
- 2010-07-22 EP EP13194273.2A patent/EP2770061B1/en active Active
- 2010-07-22 RS RS20140158A patent/RS53257B2/sr unknown
- 2010-07-23 US US12/842,609 patent/US20110064763A1/en not_active Abandoned
-
2011
- 2011-10-20 US US13/277,900 patent/US8187872B2/en active Active
-
2012
- 2012-01-22 IL IL217679A patent/IL217679A/en active IP Right Grant
-
2014
- 2014-04-02 SM SM201400041T patent/SMT201400041B/xx unknown
- 2014-04-04 HR HRP20140327TT patent/HRP20140327T4/hr unknown
-
2015
- 2015-01-20 JP JP2015008415A patent/JP6170952B2/ja not_active Expired - Fee Related
- 2015-02-27 HK HK15102018.7A patent/HK1201557A1/xx not_active IP Right Cessation
- 2015-10-01 US US14/872,633 patent/US20160076055A1/en not_active Abandoned
-
2017
- 2017-01-17 JP JP2017005594A patent/JP2017060535A/ja not_active Withdrawn
-
2018
- 2018-08-20 JP JP2018153946A patent/JP6701280B2/ja not_active Expired - Fee Related
- 2018-11-27 HR HRP20181996TT patent/HRP20181996T1/hr unknown
- 2018-12-27 CY CY20181101398T patent/CY1121159T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121159T1 (el) | Μη-ενσωματουμενοι λεντiϊικοι φορεις | |
CY1120911T1 (el) | Παραγομενες απο mdck κυτταρικες σειρες προσαρμοσμενες σε απαλλαγμενη απο ορο καλλιεργεια και καλλιεργεια εναιωρηματος και μεθοδος για παρασκευη ιου εμβολιου χρησιμοποιωντας τα κυτταρα | |
CY1120136T1 (el) | Μεθοδος για την αυξηση της ανοσοδραστικοτητας | |
CY1111378T1 (el) | Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna | |
CY1120237T1 (el) | Παρασκευασματα rna που περιλαμβανουν καθαρισμενο τροποποιημενο rna για επαναπρογραμματισμο κυτταρων | |
MX2018008413A (es) | Virus oncolitico modificado. | |
CY1116835T1 (el) | Νεο ευρωπαϊκο στελεχος toy prrsv | |
CY1124927T1 (el) | Ανακυκλωση του συνθετου μητρας πολυμερους | |
CY1119173T1 (el) | Νεα μορια αναστολεα jnk | |
BR112013011194A2 (pt) | partículas de glicoproteína semelhantes a vírus (vlps) da raiva. | |
WO2009121004A3 (en) | Neutralizing molecules to viral antigens | |
CY1114736T1 (el) | Προερχομενες απο παπια εμβρυϊκες βλαστικες κυτταρικες σειρες για την παραγωγη ιικων εμβολιων | |
EA201390806A1 (ru) | Конструкция пептидного каркаса | |
PH12016500500A1 (en) | A viral vaccine and methods of manufacture thereof | |
MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
EA201390856A1 (ru) | Инактивация вирусов с применением улучшенного способа растворитель-детергент | |
IN2012DN01577A (el) | ||
NZ702146A (en) | Peptides derived from viral proteins for use as immunogens and dosage reactants | |
EA201071086A1 (ru) | Усовершенствованный способ получения вакцинных антигенов вируса гриппа | |
MX2017009812A (es) | Composiciones y metodos para inhibir infeccion viral. | |
FR2963737B1 (fr) | Procede de lyophilisation de plasma sanguin | |
CY1123424T1 (el) | Μεθοδος για την επικαλυψη σωματιδιων | |
CY1120606T1 (el) | Μπουνυαϊοι με προδρομα γονιδια κατακερματισμενης πρωτεϊνης και μεθοδοι δημιουργιας αυτων των ιων | |
MX2010005701A (es) | Metodo para producir cepa viral vacunal de un virus de la familia reoviridae. | |
WO2012031137A3 (en) | Vesicular stomatitis viruses |